CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration

✍ Scribed by McKibbin, M.; Ali, M.; Bansal, S.; Baxter, P. D.; West, K.; Williams, G.; Cassidy, F.; Inglehearn, C. F.

• Book ID: 121664239
• Publisher: BMJ Publishing Group
• Year: 2011
• Tongue: English
• Weight: 110 KB
• Volume: 96
• Category: Article
• ISSN: 0007-1161
• DOI: 10.1136/bjo.2010.193680